Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic

Putting to rest concerns regarding oral bioavailability, Arvinas showed that its first two proteolysis-targeting chimeras achieved serum levels predicted to be efficacious.

Wednesday’s presentation of Phase I data of ARV-110 for metastatic castration-resistant prostate cancer (CRPC) and ARV-471 for ER-positive, HER2-negative breast cancer, represented the first clinical data reported by Arvinas Inc. (NASDAQ:ARVN). Arvinas shares rose $2.40 (15%) to $18.79 Wednesday...